ARTICLE | Company News
Lilly gets Chinese commercialization rights to Chi-Med compound
October 9, 2013 11:42 PM UTC
Hutchison China MediTech Ltd. (LSE:HCM) granted Eli Lilly and Co. (NYSE:LLY) rights to commercialize Chi-Med's fruquintinib ( HMPL-013) in China. The small molecule that selectively inhibits the tyros...